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August 11, 2009:661–8latelet aggregation parameters with light transmission aggregom-
try (2,3) and point-of-care, VerifyNow P2Y12 assay (Accumet-
ics, San Diego, California) (4). In a previous publication (5), the
uthors demonstrated a good correlation between MEA and light
ransmission aggregometry results. Do the obtained values in that
opulation fit a normal distribution? Can any distinctive method-
logical characteristics of the MEA system explain this finding?
Another intriguing observation, conflicting with the published
vidence (6), is the significantly higher proportion of active
mokers in the group of low (upper quintile) responders to
lopidogrel. We should expect a higher rate of active smokers
mong patients presenting with acute myocardial infarction, which
as also related to lower response in the current study. It would be
ery interesting to know the individual influence of these variables
y performing a multivariate analysis considering lower response to
lopidogrel as the dependent variable.
Stent thrombosis (ST) is probably the most feared complication
fter percutaneous coronary intervention, irrespective of the time
f appearance. Early ST (acute and subacute) still occurs despite
he aggressive use of antiplatelet agents. Apart from adherence to
he antiplatelet treatment and platelet aggregation response, some
actors have been correlated with ST (7): lower left ventricle
jection fraction, smaller diameter of the reference vessel, longer
tent lengths, and lower final pressure to implant the stents. The
uthors of the present study (1) focus the statistical analysis on the
elations of different demographic, clinical, and procedural vari-
bles with the platelet aggregation values obtained with MEA.
owever, no data about the relationship between those variables
nd ST is provided. Do the previously published or any other
ariables correlate with ST? It sounds plausible that procedural and
ngiographic variables may play an important role in the develop-
ent of ST, especially in the case of early ST. A Cox proportional
azards model that includes the above-mentioned variables could
e very helpful to detect all the independent predictors of ST.
We absolutely agree with the authors that low response to
lopidogrel (or high post-treatment platelet reactivity) may iden-
ify patients at higher risk of stent thrombosis. But all the
echanisms and related factors should be clarified to better
revent ischemic cardiac events.
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eply
e appreciate the comments made by Dr. Perez de Prado and
olleagues concerning our recent article (1).
The observation of normally distributed platelet aggregation
PA) values is only an in vitro phenomenon depending on the
opulation studied and the method applied. Indeed, PA measure-
ents were not normally distributed in our study population (1),
nd in a previous study (2) we undertook with multiple electrode
latelet aggregometry (MEA) on the Multiplate analyzer
Dynabyte GmbH, Munich, Germany). This is in contrast to
bservations made with light transmission aggregometry (LTA)
nd the VerifyNow P2Y12 assay (Accumetrics, San Diego, Cali-
ornia). In MEA, adhesion and PA leads to an increased imped-
nce signal; the more platelets that adhere to the electrode, the
igher the impedance. Hence, MEA measurements have no
nherent upper limit, and this is likely to explain not normally
istributed PA data with MEA.
In fact, the observation of a higher proportion of active smokers
n the group of clopidogrel low responders (1) is in contrast to a
ecently published study using LTA and finding lower PA values
n active smokers compared with nonsmokers (3). For LTA, it
ust be kept in mind that platelet-rich plasma is an artificial
ilieu lacking erythrocytes, leukocytes, and larger platelet subspe-
ies, all of which influence the amount of PA (4). The link of
moking and leukocytosis is well known, and also the interaction of
eukocytes and platelets in atherothrombotic processes has been
stablished (5). Endothelial dysfunctions and platelet hyper-
eactivity have been well described in smokers, as well as a negative
ffect of smoking on the pharmacokinetics of clopidogrel (6). In
ight of this conflicting data, the issue of smoking and clopidogrel
esponse warrants further investigations, which we are currently
ndertaking in separate studies.
Concerning predictors of stent thrombosis (ST), we are aware
hat other variables apart from the ones included in our primary
nalysis may play a role in this setting. ST is a very rare event, and
comprehensive analysis on its predictors requires thousands of
atients. This was beyond the scope of our study, which was
esigned to assess the relationship of MEA measurements and ST.
s requested, however, by Dr. Perez de Prado and colleagues, we
xpanded the multivariable analysis by adding the suggested
ariables (ejection fraction [already included], vessel diameter, total
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August 11, 2009:661–8tent length, and final pressure to implant the stent) into the Cox
roportional hazards model. Even after inclusion of these variables,
EA measurements maintained their highly significant prediction
alue for the occurrence of ST (hazard ratio: 12.0, 95% confidence
nterval: 2.3 to 63.2; p  0.003).
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